- Home
- / Lonza
Lonza
Stock Price
CHF543.2
2024-10-29
Market Capitalization
CHF39.2 B
2024-10-29
Revenue
CHF6.5 B
FY, 2025
Lonza Summary
Company Summary
- Overview
- Lonza Group is a company specializing in life sciences and biotechnology solutions. It provides drug substance and drug product development, biologics manufacturing, small-molecule synthesis, cell and gene therapy manufacturing, and related specialized services.
- Type
- Public
- Status
- Active
- Founded
- 1897
- HQ
- Basel, CH | view all locations
- Website
- https://www.lonza.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Philippe Deecke, Chief Financial Officer and Member of the Executive Committee
Ulrike Kaeppler, Chief Human Resources Officer and Member of the Executive Committee
Daniel Palmacci, President, Cell & Gene and Member of the Executive Committee
Operating MetricsView all
Large-Molecule Clinical Development Programs (Biologics)
600
16.5%
FY, 2022
Clinical Small-Molecule Programs (Small-Molecule Businesses)
225
15.1%
FY, 2022
Countries
28
6.7%
FY, 2022
LocationsView all
59 locations detected
Basel, BS HQ
Switzerland
Münchensteinerstrasse 38
Bend, OR
United States
63045 NE Corporate Pl
Cambridge, MA
United States
50 Hampshire St
Cohasset, MN
United States
1101 NW 3rd St
Greenwood, SC
United States
535 Emerald Rd N
Houston, TX
United States
14905 Kirby Dr
Lonza Financials
Summary Financials
- Revenue (FY, 2025)
- CHF6.5B
- Gross profit (FY, 2025)
- CHF4.5B
- Net income (FY, 2025)
- CHF909.0M
- Cash (FY, 2025)
- CHF719.0M
- EBIT (FY, 2025)
- CHF1.3B
- Enterprise value
- $43.0B
Competitors and Similar Companies
- Nissan ChemicalManufacturing & Industrial - Public
- NovozymesManufacturing & Industrial - Subsidiary
- WuXi BiologicsManufacturing & Industrial - Public
- DuPontManufacturing & Industrial - Public
- Bristol Myers SquibbHealthcare - Public
- CatalentManufacturing & Industrial - Subsidiary
- DSMManufacturing & Industrial - Subsidiary
- Divis LaboratoriesHealthcare - Public